Navamedic ASA - Company Profile

Powered by

All the sales intelligence you need on Navamedic ASA in one solution.

$ $295
Register your interest Learn more
  • Save hours of research time with a comprehensive
    Sales Intelligence Solution.

  • Understand how Navamedic ASA fits into your total
    addressable market and Ideal Customer Profile.

  • Gain competitive edge with triggers that tell you
    when and how to engage with Navamedic ASA.

Back to companies

Navamedic ASA: Overview

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Select Item

Navamedic ASA (Navamedic) develops, produces, and commercializes medicines and related products. It offers products in branded generics, speciality pharma, medical nutrition and consumer health. The company’s major products include Mysimba, a prescription treatment for obesity, Imdur, a drug for angina, and Modifast, a range of low-calorie meal replacement products. In speciality pharma and consumer health, the company focuses on specific categories like women’s health, cardiology, gastro, obesity, cough and cold, urology, dermatology, wound care and pain relief. Navamedic offers products to patients, hospitals, wholesalers and pharmacy chains in the Nordic, Benelux, Baltic countries and other European nations, including the UK and Greece. The company collaborates with international companies for in-licensing or out-licensing across the Nordics and Benelux regions. Navamedic is headquartered in Oslo, Norway.

 Gain a 360-degree view of Navamedic ASA and make more informed decisions for your business Gain a 360-degree view of Navamedic ASA and make more informed decisions for your business Learn more
Headquarters Norway
Address Henrik Ibsens Gate 100, Oslo, 0255
Website www.navamedic.com
Telephone 47 67 112540
No of Employees 45
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange NAVA (OSL)
Revenue (2024) $49.4M 3.8% (2024 vs 2023)
EPS XYZ
Net Income (2024) XYZ 59.9% (2024 vs 2023)
Market Cap* $49.7M
Net Profit Margin (2024) XYZ 61.4% (2024 vs 2023)
* As of and is in US$
View Navamedic ASA financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Learn more

Navamedic ASA premium industry data and analytics

8

Marketed Drugs

Understand Navamedic ASA’s commercialized product portfolio to stay one step ahead of the market.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Navamedic ASA’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Services Brands
Consumer Health: In-licensing OraFID
Gastro Out-licensing Flexilev
Pain Relief Eroxon
XYZ XYZ
XYZ XYZ
XYZ XYZ
Understand Navamedic ASA portfolio and identify potential areas for collaboration Understand Navamedic ASA portfolio and identify potential areas for collaboration Learn more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2025 New Products/Services In December, the company launched Flexilev in OraFID Enhancing Parkinson’s Care with Simplified and Precise Dosing for Personalized Treatment.
2025 Contracts/Agreements In October, the company entered into an agreement with German pharma company Evolsin Medical to launch new products in Germany.
2025 Regulatory Approval In October, the company received regulatory approval for Flexilev in OraFID that is fully mechanical medical device granted across all Nordic countries.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Learn more
Image for loader

Competitor Comparison

Key Parameters Navamedic ASA Orifarm Group A/S Photocure ASA Napp Pharmaceuticals Ltd AxiCorp GmbH
Headquarters Norway Denmark Norway United Kingdom Germany
City Oslo Odense Oslo Cambridge Friedrichsdorf
State/Province - - - England Hessen
No. of Employees 45 2,372 101 32 270
Entity Type Public Private Public Private Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Learn more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Learn more
Executives
Name Position Board Since Age
Morten Jurs Chairman Executive Board - 66
Kathrine Gamborg Andreassen Chief Executive Officer Senior Management 2019 60
Nils Ole Krekling Chief Financial Officer Senior Management 2026 42
Alexander Lidmejer Chief Operating Officer Senior Management 2024 45
Astrid T. Bratvedt Chief Scientific Officer Senior Management 2019 63
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Gain insight into Navamedic ASA key executives to enhance your sales strategy Gain insight into Navamedic ASA key executives to enhance your sales strategy Learn more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Why are you leaving?